{
  "run_date": "2026-02-08T16:44:29.198841+00:00",
  "stocks_scanned": 235,
  "top_picks": [
    {
      "ticker": "TKA",
      "name": "thyssenkrupp AG",
      "exchange": "XETR",
      "index": "DAX",
      "sector": "Industrials",
      "price": 11.655,
      "currency": "EUR",
      "market_cap": 9659455488,
      "pe_ratio": 15.54,
      "forward_pe": 10.92704,
      "roe": 5.0869998,
      "dividend_yield": 129.0,
      "momentum_6m": 19.602403566203286,
      "momentum_12m": 157.50894348275168,
      "rsi_14": 66.40772694967322,
      "alpha_score": 82,
      "score_breakdown": {
        "value": 21,
        "quality": 15,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 8
      },
      "yahoo_url": "https://finance.yahoo.com/quote/TKA.DE",
      "signal": "HOLD",
      "confidence": "MEDIUM",
      "reasoning": "ThyssenKrupp AG is a German industrial conglomerate with operations across steel, materials services, automotive technology, marine systems, and decarbonization technologies. The company returned to profitability in fiscal 2025 with net income of 532 million euros after a prior-year loss, though it faces a challenging market environment with declining sales and order intake in Q4 2025[1]. Management projects a net loss of 400-800 million euros for fiscal 2026, primarily driven by restructuring provisions at Steel Europe[1].",
      "company_overview": "ThyssenKrupp AG is a German industrial conglomerate with operations across steel, materials services, automotive technology, marine systems, and decarbonization technologies. The company returned to profitability in fiscal 2025 with net income of 532 million euros after a prior-year loss, though it faces a challenging market environment with declining sales and order intake in Q4 2025[1]. Management projects a net loss of 400-800 million euros for fiscal 2026, primarily driven by restructuring provisions at Steel Europe[1].",
      "key_developments": [
        "**Q4 2025 Results (January 2026):** ThyssenKrupp reported Q4 net income of 639 million euros per share (1.03 euros) versus a prior-year loss, with adjusted EBIT climbing 82% to 274 million euros. However, Q4 sales fell 6% to 8.28 billion euros and order intake declined 12% to 6.98 billion euros[1]."
      ],
      "catalysts": [
        "**Q1 FY2026 Interim Report (February 12, 2026):** Immediate catalyst with analyst call providing updated guidance and visibility into current trading conditions."
      ],
      "risk_factors": [
        "**Cyclical Downturn:** The company explicitly cites a \"persistently challenging market environment\" with expected sales declines at Automotive Technology and Decarbon Technologies, suggesting exposure to broader industrial weakness[1]."
      ],
      "sources": [
        "https://www.nasdaq.com/articles/thyssenkrupp-turns-profit-q4-sales-orders-down-sees-loss-weak-sales-fy26",
        "https://stockinvest.us/stock/TKA.DE",
        "https://www.thyssenkrupp.com/en/investors/calendar",
        "https://www.thyssenkrupp.com/en/investors",
        "https://www.thyssenkrupp.com/en/investors/reporting-and-publications",
        "https://simplywall.st/stocks/de/materials/etr-tka/thyssenkrupp-shares/past",
        "https://www.marketscreener.com/quote/stock/THYSSENKRUPP-AG-436698/finances/",
        "https://eulerpool.com/en/stock/thyssenkrupp-Stock-DE0007500001/NetIncome"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "EN",
      "name": "Bouygues SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 48.25,
      "currency": "EUR",
      "market_cap": 18544437248,
      "pe_ratio": 17.545454,
      "forward_pe": 13.719469,
      "roe": 8.397,
      "dividend_yield": 415.00000000000006,
      "momentum_6m": 25.84767816372373,
      "momentum_12m": 60.73101046194995,
      "rsi_14": 69.28839450740628,
      "alpha_score": 78,
      "score_breakdown": {
        "value": 21,
        "quality": 9,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/EN.PA",
      "signal": "BUY",
      "confidence": "MEDIUM",
      "reasoning": "Bouygues SA is a French multinational conglomerate operating across telecommunications, media, and construction sectors with a market capitalization of \u20ac15.19 billion[2]. The company reported revenue of \u20ac56.80 billion in 2024 (up 1.32% year-over-year) and net income of \u20ac1.06 billion (up 1.73%)[2]. The stock has demonstrated strong momentum, gaining 60.7% over the past 12 months and 25.8% over the past 6 months, currently trading at \u20ac48.25 with a P/E ratio of 17.5[2].",
      "company_overview": "Bouygues SA is a French multinational conglomerate operating across telecommunications, media, and construction sectors with a market capitalization of \u20ac15.19 billion[2]. The company reported revenue of \u20ac56.80 billion in 2024 (up 1.32% year-over-year) and net income of \u20ac1.06 billion (up 1.73%)[2]. The stock has demonstrated strong momentum, gaining 60.7% over the past 12 months and 25.8% over the past 6 months, currently trading at \u20ac48.25 with a P/E ratio of 17.5[2].",
      "key_developments": [
        "**Nine-month 2025 results (November 5, 2025)**: Bouygues reported strong construction sales with financial resilience, though nine-month profit declined while sales increased 0.9% year-over-year[2]. The company maintained its full-year 2025 outlook despite macroeconomic uncertainty."
      ],
      "catalysts": [
        "**Full-year 2025 earnings release (February 26, 2026)**: Upcoming earnings announcement will provide clarity on whether the company achieved its stated guidance for slight increases in COPA (current operating profit after amortization) and sales[2]."
      ],
      "risk_factors": [
        "**Profit margin pressure**: Nine-month 2025 profit declined despite sales growth, indicating margin compression that could persist if operational efficiency doesn't improve[2]."
      ],
      "sources": [
        "https://stockinvest.us/stock/BOUYY",
        "https://stockanalysis.com/quote/epa/EN/",
        "https://live.euronext.com/en/products/equities/company-news/2026-02-02-bouygues-monthly-disclosure-total-number-shares-and",
        "https://www.globenewswire.com/news-release/2026/02/02/3230458/0/en/bouygues-monthly-disclosure-of-the-total-number-of-shares-and-voting-rights.html",
        "https://ng.investing.com/equities/bouygues-n-historical-data",
        "https://www.otcmarkets.com/stock/BOUYF/news"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "AZN",
      "name": "AstraZeneca PLC",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Healthcare",
      "price": 14104.0,
      "currency": "GBP",
      "market_cap": 218651983872,
      "pe_ratio": 31.623316,
      "forward_pe": 18.686577,
      "roe": 21.674,
      "dividend_yield": 173.0,
      "momentum_6m": 27.799927509967382,
      "momentum_12m": 20.387470630408732,
      "rsi_14": 54.043839758125465,
      "alpha_score": 75,
      "score_breakdown": {
        "value": 5,
        "quality": 22,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/AZN.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "AstraZeneca's NYSE listing enhances liquidity and US investor access, aligning with strong recent performance (27.8% 6-month return) and a high-quality pipeline poised for $10+ billion peak revenues, supporting the 2030 $80 billion ambition.[1][user query] Quality and momentum factors in the Alpha Score (22 and 25 points) reinforce a favorable trajectory despite a premium valuation (P/E 31.6).[user query] This positions AZN for continued outperformance in a healthcare sector favoring innovative biopharma leaders.",
      "company_overview": "AstraZeneca PLC is a global biopharmaceutical company focused on oncology, rare diseases, and bioPharmaceuticals, with a strong market position evidenced by recent robust growth and a harmonized global listing structure across NYSE, LSE, and Nasdaq Stockholm under the AZN ticker.[1] The company trades at a P/E of 31.6 with ROE of 21.7%, reflecting solid profitability amid 27.8% 6-month and 20.4% 12-month returns, supported by an Alpha Score of 75/100 driven by quality and momentum.[user query] Management expresses confidence in its pipeline, highlighting readouts with over $10 billion peak revenue potential and a 2030 ambition of $80 billion annual revenue alongside 20 new medicine launches.[1]",
      "key_developments": [
        "AstraZeneca commenced trading of its ordinary shares on the NYSE under the AZN ticker, creating a harmonized global listing with existing LSE and Nasdaq Stockholm listings to access the world's largest capital market and broaden its investor base.[1]",
        "The NYSE listing replaces the prior American Depositary Share (ADS) structure, with US dollar bonds also transitioning to NYSE trading; UK and Swedish listings and index memberships remain unchanged.[1]",
        "No other developments explicitly noted in the last 30 days, though the NYSE launch underscores ongoing strategic expansion amid reiterated long-term growth targets.[1]"
      ],
      "catalysts": [
        "Pipeline readouts from high-potential programs, representing over $10 billion in stated peak revenue opportunity.[1]",
        "Progress toward 2030 goals, including launches of 20 new medicines, with potential updates in upcoming earnings or filings.[1]"
      ],
      "risk_factors": [
        "Elevated P/E ratio (31.6) may pressure valuation if growth expectations falter amid market volatility or sector headwinds.[user query]",
        "Execution risks on ambitious 2030 targets ($80 billion revenue), including regulatory hurdles or clinical trial setbacks not detailed in recent filings.[1]"
      ],
      "sources": [
        "https://www.stocktitan.net/sec-filings/AZN/6-k-astrazeneca-plc-current-report-foreign-issuer-5cf8521c5fa8.html"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "DG",
      "name": "Vinci SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 134.2,
      "currency": "EUR",
      "market_cap": 74474168320,
      "pe_ratio": 15.496535,
      "forward_pe": 13.201904,
      "roe": 15.433,
      "dividend_yield": 373.0,
      "momentum_6m": 8.321016006141392,
      "momentum_12m": 30.518547803182727,
      "rsi_14": 84.94207993778656,
      "alpha_score": 72,
      "score_breakdown": {
        "value": 21,
        "quality": 16,
        "momentum": 20,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/DG.PA",
      "signal": "HOLD",
      "confidence": "MEDIUM",
      "reasoning": "Vinci is a French construction and infrastructure company with significant exposure to concessions and services across Europe and globally. The company delivered **outstanding 2025 performance** with revenue of \u20ac74.60 billion (4.2% growth) and net profit of \u20ac4.90 billion, exceeding analyst consensus estimates[1]. However, approximately 50% of net profit is generated in France, creating material exposure to French tax policy changes[3].",
      "company_overview": "Vinci is a French construction and infrastructure company with significant exposure to concessions and services across Europe and globally. The company delivered **outstanding 2025 performance** with revenue of \u20ac74.60 billion (4.2% growth) and net profit of \u20ac4.90 billion, exceeding analyst consensus estimates[1]. However, approximately 50% of net profit is generated in France, creating material exposure to French tax policy changes[3].",
      "key_developments": [
        "**Record free cash flow of \u20ac7.01 billion** in 2025, significantly exceeding prior year (\u20ac6.81 billion) and analyst expectations (\u20ac4.72 billion predicted)[1][5], demonstrating strong cash generation capability."
      ],
      "catalysts": [
        "**2026 earnings trajectory** - Management expects continued revenue and earnings growth; delivery against these targets will validate or challenge BofA's cautious outlook."
      ],
      "risk_factors": [
        "**French tax exposure** - Approximately 50% of net profit generated in France creates significant vulnerability to corporate tax increases or infrastructure tax changes, a primary concern cited in BofA's downgrade[3]."
      ],
      "sources": [
        "https://www.marketscreener.com/news/vinci-shares-jump-after-revenue-increase-record-free-cash-flow-ce7e5ad9d88bf126",
        "https://stockinvest.us/stock/DG.PA",
        "https://www.investing.com/news/analyst-ratings/vinci-stock-downgraded-to-underperform-by-bofa-on-french-tax-risks-93CH-4443975",
        "https://www.morningstar.com/stocks/xpar/dg/quote",
        "https://www.smartkarma.com/home/newswire/earnings-alerts/vinci-sa-dg-earnings-fy-revenue-aligns-with-estimates-and-exceeds-free-cash-flow-expectations/",
        "https://www.vinci.com/en/vinci/page/cours_de_l_action",
        "https://www.marketbeat.com/stocks/EPA/DG/"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "FERG",
      "name": "Ferguson Enterprises Inc.",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Industrials",
      "price": 19170.0,
      "currency": "GBP",
      "market_cap": 38471598080,
      "pe_ratio": 26.260273,
      "forward_pe": 23.252579,
      "roe": 33.404,
      "dividend_yield": 138.0,
      "momentum_6m": 16.616244059754326,
      "momentum_12m": 31.685590830856224,
      "rsi_14": 64.28571428571428,
      "alpha_score": 71,
      "score_breakdown": {
        "value": 9,
        "quality": 22,
        "momentum": 25,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/FERG.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Ferguson Enterprises is a leading distributor of plumbing, heating, ventilation, air conditioning (HVAC), and waterworks products across North America, with significant exposure to both residential and non-residential construction markets. The company has demonstrated strong operational momentum, with Q1 2026 (quarter ended October 31, 2025) delivering robust profitability gains despite modest revenue growth, supported by margin expansion and strategic acquisitions like Moore Supply Company[1][2]. Ferguson's balance sheet remains healthy with net debt to EBITDA at 1.1x, positioning it well for continued investment and shareholder returns[3].",
      "company_overview": "Ferguson Enterprises is a leading distributor of plumbing, heating, ventilation, air conditioning (HVAC), and waterworks products across North America, with significant exposure to both residential and non-residential construction markets. The company has demonstrated strong operational momentum, with Q1 2026 (quarter ended October 31, 2025) delivering robust profitability gains despite modest revenue growth, supported by margin expansion and strategic acquisitions like Moore Supply Company[1][2]. Ferguson's balance sheet remains healthy with net debt to EBITDA at 1.1x, positioning it well for continued investment and shareholder returns[3].",
      "key_developments": [
        "**Q1 2026 earnings beat on profitability**: Adjusted diluted EPS of $2.84 exceeded consensus estimates of $2.62-$2.77, representing 15.9% year-over-year growth, though the stock initially declined 3-4% in premarket trading, suggesting investor disappointment relative to higher expectations[1][4][5]"
      ],
      "catalysts": [
        "**Full-year 2025 guidance execution**: Management maintained 5% revenue growth guidance while narrowing operating margin guidance to 9.4-9.6% (from 9.2-9.6%), providing a clear performance benchmark for the remainder of the fiscal year[2][4]"
      ],
      "risk_factors": [
        "**Residential market deterioration**: The 1% decline in residential revenue (50% of US sales) signals potential headwinds; further weakness in this segment could offset non-residential strength and pressure overall profitability[4]"
      ],
      "sources": [
        "https://www.quiverquant.com/news/Ferguson+Enterprises+(FERG)+Earnings:+Q1+2026+EPS+Beats+as+Profits+Rise",
        "https://www.moomoo.com/news/post/62629271/ferguson-enterprises-inc-ferg-q1-2026-earnings-call-transcript-summary",
        "https://quartr.com/companies/ferguson-enterprises-inc_3672",
        "https://www.investing.com/news/company-news/ferguson-q1-2026-slides-eps-miss-triggers-stock-decline-despite-revenue-beat-93CH-4398910",
        "https://www.youtube.com/watch?v=ZKruzocZHyc",
        "https://www.corporate.ferguson.com/investor/events-results-and-reports/default.aspx",
        "https://www.corporate.ferguson.com/investor/why-ferguson/default.aspx",
        "https://www.corporate.ferguson.com/pressroom/news-releases/news-details/2025/Ferguson-Reports-Quarter-Ended-October-31-2025/default.aspx",
        "https://www.marketbeat.com/stocks/NYSE/FERG/earnings/"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "ENR",
      "name": "Siemens Energy AG",
      "exchange": "XETR",
      "index": "DAX",
      "sector": "Industrials",
      "price": 152.0,
      "currency": "EUR",
      "market_cap": 130012315648,
      "pe_ratio": 95.0,
      "forward_pe": 28.98324,
      "roe": 16.816,
      "dividend_yield": 46.0,
      "momentum_6m": 58.33333333333333,
      "momentum_12m": 166.19965685093595,
      "rsi_14": 71.95574684426185,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 22,
        "momentum": 23,
        "catalyst": 13,
        "liquidity": 7
      },
      "yahoo_url": "https://finance.yahoo.com/quote/ENR.DE",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "**BULLISH** - **Confidence: HIGH**   Siemens Energy's trajectory reflects structural tailwinds from global grid modernization and energy transition, bolstered by record orders, margin expansion, and analyst upgrades to \u20ac164-\u20ac170 targets above the current \u20ac152 price.[1][2] FY2026 guidance and raised FY2028 outlook indicate sustained profitable growth, with technicals showing strength above key moving averages despite elevated valuations (P/E 95x).[1][3] Strong momentum (+58% 6m, +166% 12m) and buy ratings outweigh wind segment risks, supporting further upside in a favorable macro environment.[1]",
      "company_overview": "",
      "key_developments": [
        "Deutsche Bank raised its price target to **\u20ac170** from \u20ac135 on 29 January 2026, citing improved fundamentals, stronger order pipeline, and profitability outlook tied to grid and energy-transition demand.[1]",
        "Jefferies lifted its target to **\u20ac164** from \u20ac134 on 2 February 2026, highlighting better earnings visibility and supportive sector dynamics in grid investments.[1]",
        "Released strong **Q4 FY2025 results** (fiscal year ending 31 December 2025), meeting upgraded full-year guidance at the upper end, raising mid-term FY2028 targets to **14-16% profit margin** (from 10-12%) and low-teens comparable revenue CAGR (from high single-digit to low double-digit), with FY2026 outlook for **11-13% revenue growth** and **9-11% profit margin**.[2]",
        "Announced **\u20ac6bn share repurchase program** through FY2028 end and early dividend payout after exiting federal guarantee, signaling confidence in cash flow and shareholder returns.[2]"
      ],
      "catalysts": [
        "Full **FY2025 earnings release and analyst conference** details, expected to reinforce upper-end guidance and mid-term upgrades.[2]",
        "Progress on **\u20ac6bn share buyback initiation** and first dividend payment, enhancing shareholder value.[2]",
        "Potential further broker upgrades or order announcements amid rising grid/energy-transition spending.[1]"
      ],
      "risk_factors": [
        "Persistent challenges in the **legacy onshore wind business** (Siemens Gamesa), including project execution risks that could pressure margins.[1]",
        "Elevated valuation (P/E **95x** vs. sector 24x) leaves room for pullbacks if delivery falters or macro sentiment shifts, with RSI near 72 signaling overbought conditions.[1][3]",
        "Broader energy sector uncertainties, such as supply chain issues or slower transition spending.[1]"
      ],
      "sources": [
        "https://capital.com/en-int/analysis/siemens-energy-stock-forecast",
        "https://www.siemens-energy.com/global/en/home/investor-relations.html",
        "https://www.investing.com/equities/siemens-energy-ag",
        "https://www.stockopedia.com/share-prices/siemens-energy-ag-ETR:ENR/news/"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "SAF",
      "name": "Safran SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 308.0,
      "currency": "EUR",
      "market_cap": 128284680192,
      "pe_ratio": 29.758453,
      "forward_pe": 29.628347,
      "roe": 34.745997,
      "dividend_yield": 94.0,
      "momentum_6m": 5.987609611503686,
      "momentum_12m": 26.409959646058656,
      "rsi_14": 39.782594994443805,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 25,
        "momentum": 20,
        "catalyst": 13,
        "liquidity": 7
      },
      "yahoo_url": "https://finance.yahoo.com/quote/SAF.PA",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Safran's leadership in high-demand aerospace propulsion and equipment, bolstered by CFM's narrow-body engine dominance and strong profitability (ROE 27.93-34.7%), positions it for growth amid global aviation recovery.[1][2] Morningstar's \u20ac391 fair value suggests ~28% upside from ~\u20ac300 levels, outweighing premium multiples versus peers like RTX (P/E 31.82).[2] Recent buyback reinforces shareholder value in a sector with solid momentum (Alpha Score 70/100).[4]",
      "company_overview": "Safran SA is a leading global player in aerospace propulsion, aircraft equipment, defense, and interiors, operating through three segments: Aerospace Propulsion (engines and spares via CFM joint venture with GE), Aircraft Equipment/Defense/Aerosystems (landing gear, avionics, etc.), and Aircraft Interiors (seats, cabins, IFEC).[1][2] Headquartered in Paris with 96,390 employees, it holds a strong market position in commercial and military aviation, trading at a premium valuation (P/E 38.74 normalized, Price/Book 9.47) amid robust ROE of ~28-35% and recent 12-month returns of +26.4%.[1][2] The stock is near its 52-week high (~\u20ac308), supported by aerospace recovery but facing medium uncertainty per Morningstar.[2]",
      "key_developments": [
        "On January 13, 2026, Safran announced a share buyback agreement with an investment services provider for cancellation, signaling confidence in its valuation and capital return strategy.[4]",
        "Stock price rose +1.82% to \u20ac308 on February 6, 2026, with recent trading (e.g., Feb 4 close at \u20ac307.80) showing stability near highs amid sector peers like RTX and GE.[3][6]",
        "No other major developments reported in the last 30 days; focus remains on ongoing aerospace demand and financial metrics like 0.97% dividend yield.[2]"
      ],
      "catalysts": [
        "Q4/Full-year 2025 earnings release (likely Feb/Mar 2026), potentially highlighting propulsion aftermarket growth and CFM order backlog.[1][2]",
        "Aviation sector tailwinds, including aircraft delivery ramps from Airbus/Boeing partners and defense spending increases.[2]"
      ],
      "risk_factors": [
        "Elevated valuation (546% Morningstar premium, analyst upside only 6.1%) vulnerable to aerospace supply chain disruptions or demand slowdowns.[1][2]",
        "Geopolitical tensions or economic slowdown impacting military/commercial orders, with medium uncertainty rating.[2]"
      ],
      "sources": [
        "https://www.investing.com/equities/safran",
        "https://www.morningstar.com/stocks/xpar/saf/quote",
        "https://www.safran-group.com/finance/safran-share-price",
        "https://www.safran-group.com/pressroom/share-buyback-cancellation-2026-01-13",
        "https://www.safran-group.com/finance/glance",
        "https://markets.ft.markitdigital.com/data/equities/tearsheet/historical?s=SAF%3APAR"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "GSK",
      "name": "GSK plc",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Healthcare",
      "price": 2198.0,
      "currency": "GBP",
      "market_cap": 88211988480,
      "pe_ratio": 15.812949,
      "forward_pe": 11.246936,
      "roe": 43.310001,
      "dividend_yield": 328.0,
      "momentum_6m": 56.58391015225654,
      "momentum_12m": 50.047182405412705,
      "rsi_14": 85.63432835820896,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 13,
        "quality": 19,
        "momentum": 23,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/GSK.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "GSK plc is a British pharmaceutical giant with a diversified portfolio spanning specialty medicines, vaccines, and general medicines. The company delivered strong 2025 performance with turnover rising 4% to \u00a332.6 billion and core operating profit up 11%, driven primarily by double-digit growth in its Specialty Medicines division (Respiratory, Immunology & Inflammation, Oncology, and HIV)[1][3]. Under new CEO Luke Miels (appointed January 2026), GSK is executing a strategic pivot toward higher-margin specialty medicines while managing patent expirations in its general medicines portfolio.",
      "company_overview": "GSK plc is a British pharmaceutical giant with a diversified portfolio spanning specialty medicines, vaccines, and general medicines. The company delivered strong 2025 performance with turnover rising 4% to \u00a332.6 billion and core operating profit up 11%, driven primarily by double-digit growth in its Specialty Medicines division (Respiratory, Immunology & Inflammation, Oncology, and HIV)[1][3]. Under new CEO Luke Miels (appointed January 2026), GSK is executing a strategic pivot toward higher-margin specialty medicines while managing patent expirations in its general medicines portfolio.",
      "key_developments": [
        "**Q4 2025 Results Beat Expectations**: GSK reported Q4 core EPS of 68 cents (beating consensus of 64 cents) and revenue of $11.46 billion (\u00a38.62 billion), with specialty medicines sales rising 18% driven by strong demand for HIV, oncology, and respiratory products including Dovato, Cabenuva, Apretude, Jemperli, Nucala, and Trelegy[2]."
      ],
      "catalysts": [
        "**2026 Commercial Execution**: Management has emphasized 2026 as \"a key year of execution and operational delivery with strong focus on commercial launches and accelerating R&D,\" suggesting multiple product launches and market expansions throughout the year[1]."
      ],
      "risk_factors": [
        "**Patent Cliff Exposure**: GSK faces material revenue headwinds from patent expirations in its general medicines portfolio beginning 2028, with vaccine and general medicines sales expected to decline or remain flat in 2026[2][5]. The company's ability to offset these losses through specialty medicines growth is not guaranteed."
      ],
      "sources": [
        "https://www.nasdaq.com/articles/gsk-q4-results-climb-sees-growth-fy26-backs-2031-sales-view-update",
        "https://www.zacks.com/stock/news/2828654/gsks-q4-earnings-sales-beat-estimates-stock-up-on-26-outlook",
        "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/",
        "https://www.gurufocus.com/news/8580044/gsk-projects-moderate-growth-in-turnover-and-earnings-by-2026?mobile=true",
        "https://www.voxmarkets.com/articles/gsk-sees-slower-sales-growth-in-2026-as-patent-loss-looms-7c4f7f2",
        "https://www.ig.com/uk/news-and-trade-ideas/gsk-full-year-earnings--can-the-pharma-giant-deliver-on-post-dem-260203",
        "https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "RIO",
      "name": "Rio Tinto Group",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Basic Materials",
      "price": 6843.0,
      "currency": "GBP",
      "market_cap": 111193030656,
      "pe_ratio": 14.716128,
      "forward_pe": 12.19558,
      "roe": 17.158002,
      "dividend_yield": 416.0,
      "momentum_6m": 49.673994048695945,
      "momentum_12m": 36.53139134072427,
      "rsi_14": 66.68874172185431,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 13,
        "quality": 22,
        "momentum": 25,
        "catalyst": 0,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/RIO.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Rio Tinto's pivot to copper, lithium, and growth projects like Simandou and Oyu Tolgoi positions it for earnings expansion amid energy transition demand, with H1 2025 resilience and undervaluation (19% DCF upside, low P/E) supporting outperformance versus peers.[1][3] Strong balance sheet (ROE 20.3%, debt/equity 23.9%) and $10-11 billion mid-term capex enable long-term value creation despite iron ore volatility, with 2026 net income forecast at $12.66 billion (+16.6% YoY).[2][7]",
      "company_overview": "Rio Tinto Group is a leading global mining company focused on iron ore, aluminium, copper, and emerging battery metals like lithium, with strong market positions in high-quality assets such as Pilbara iron ore and Oyu Tolgoi copper. In H1 2025, it reported resilient Underlying EBITDA of $11.5 billion despite a 13% drop in iron ore prices, driven by growth in aluminium (50% EBITDA uplift) and copper (69% uplift), though free cash flow fell 31% to $2.0 billion due to higher capex.[1] The stock has delivered strong returns (+49.7% over 6 months, +36.5% over 12 months) amid diversification efforts, trading at a P/E of 14.7x below industry averages, with DCF models indicating 19.1% undervaluation.[3]",
      "key_developments": [
        "H1 2025 results showed operational resilience with $6.9 billion operating cash flow and 60% cash conversion, offsetting iron ore weakness via copper ramp-up at Oyu Tolgoi (54% YoY production growth) and aluminium gains; net debt rose to $14.6 billion post-Arcadium Lithium acquisition.[1]",
        "Acceleration of key projects: Simandou iron ore first shipment advanced to November 2025; Oyu Tolgoi on track for 500 ktpa copper average from 2028-2036; lower copper C1 costs and ESG advances like NeoSmelt decarbonization.[1]",
        "Share price up ~33% YTD 2025 (ASX) and 11.6% over past 30 days (LSE), reflecting market recognition of undervaluation (P/E 14.47x vs. fair ratio 29.03x) and projected FCF growth to $13.6 billion by 2030.[2][3]"
      ],
      "catalysts": [
        "2025 Annual Results on 19 February 2026, potentially highlighting full-year diversification gains and project updates.[5]",
        "Simandou first iron ore shipment in November 2025, de-risking a major growth asset.[1]",
        "Oyu Tolgoi copper ramp-up milestones toward 500 ktpa from 2028, boosting output amid tight supply.[1]"
      ],
      "risk_factors": [
        "Iron ore price volatility and external headwinds like cyclones, which pressured H1 2025 EBITDA despite offsets.[1]",
        "Elevated capex ($4.7 billion H1 2025, up 18% YoY) and net debt increase post-acquisitions, heightening sensitivity to rates and FCF declines.[1][2]"
      ],
      "sources": [
        "https://www.tikr.com/blog/can-rio-tintos-aggressive-pivot-to-lithium-and-copper-projects-sustain-growth-in-2026",
        "https://www.raskmedia.com.au/2026/02/06/6-key-numbers-to-value-rio-shares-29/",
        "https://simplywall.st/stocks/gb/materials/lse-rio/rio-tinto-group-shares/news/has-the-market-fully-reflected-rio-tinto-lserios-strong-rece",
        "https://www.riotinto.com/en/invest/financial-calendar",
        "https://www.riotinto.com/en/invest/financial-news-performance",
        "https://www.riotinto.com/en/invest/reports",
        "https://eulerpool.com/en/stock/Rio-Tinto-Stock-GB0007188757/NetIncome"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "AMAT",
      "name": "Applied Materials, Inc.",
      "exchange": "US",
      "index": "NASDAQ_SELECT",
      "sector": "Technology",
      "price": 322.51,
      "currency": "USD",
      "market_cap": 255983124480,
      "pe_ratio": 37.15553,
      "forward_pe": 26.492924,
      "roe": 35.508,
      "dividend_yield": 56.99999999999999,
      "momentum_6m": 75.29526315003756,
      "momentum_12m": null,
      "rsi_14": 48.28819156800613,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 25,
        "momentum": 17,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/AMAT",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Strong AI-related demand for semiconductor equipment supports near-term growth, with recent price surges, analyst upgrades, and earnings beat history outweighing high valuation concerns.[1][2][4] However, expected YoY earnings/revenue declines and overvaluation signals (fair value ~$194-321) temper enthusiasm, positioning AMAT for upside if Q1 results exceed lowered expectations.[2][3][4] Global semiconductor capex, including TSMC flows, bolsters the equipment sector outlook despite European market caution on tech multiples.[1]",
      "company_overview": "Applied Materials, Inc. (AMAT) is a leading provider of manufacturing equipment, services, and software for the semiconductor, display, and related industries, holding a strong position in AI-driven chip production amid robust demand for advanced GPUs and digitization.[1][2] The stock has delivered exceptional performance with a 75.3% six-month return, recently surging 6.1% to $322.51 on February 6, 2026, driven by analyst upgrades and equipment boom momentum, though it trades at a high P/E of 37.2 with a market cap near $256B.[1][4] Fundamentals remain solid, with Q4 FY2025 EPS beating estimates at $2.17 and ROE at 35.5-39.26%, but revenue dipped 3.5% year-over-year.[1]",
      "key_developments": [
        "Shares jumped 6.1% on February 6, 2026, to $322.51 (high $324.40) amid \"Equipment Trio\" rally with peers, fueled by AI chip manufacturing capacity bottlenecks.[1][4]",
        "Multiple analyst upgrades in recent months: Deutsche Bank to $390 (Buy, Jan 23), KeyCorp to $380 (Overweight, Jan 16), Morgan Stanley to $364 (Overweight), consensus Moderate Buy at $315.15 average target.[1]",
        "Recent session drop of 2.96% to $318.67 amid broader market weakness, ahead of Q1 FY2026 earnings on February 12.[5]"
      ],
      "catalysts": [
        "Q1 FY2026 earnings on February 12, with EPS guidance $1.98-$2.38 and consensus $2.19; potential beat could drive further gains amid AI hype.[1][3]",
        "AI chip equipment spending surge and broker reiterations on EV/digitization demand post-earnings.[2][4]"
      ],
      "risk_factors": [
        "Year-over-year earnings decline (EPS -7.98%, revenue -4.34%) and high expectations could trigger sell-off if Q1 misses.[3][5]",
        "US-China export controls and potential semiconductor capex pullback, exacerbating overvaluation (fair value estimates $194-321 vs. current $322).[2]"
      ],
      "sources": [
        "https://www.marketbeat.com/instant-alerts/applied-materials-nasdaqamat-trading-up-61-whats-next-2026-02-06/",
        "https://simplywall.st/stocks/us/semiconductors/nasdaq-amat/applied-materials/news/a-look-at-applied-materials-amat-valuation-after-bullish-bro",
        "https://www.nasdaq.com/articles/applied-materials-amat-expected-beat-earnings-estimates-can-stock-move-higher",
        "https://www.tikr.com/blog/applied-materials-surged-6-on-equipment-boom-path-to-a-320-breakout-in-2026",
        "https://www.zacks.com/stock/news/2828386/heres-why-applied-materials-amat-fell-more-than-broader-market"
      ],
      "target_timeframe": "3-6 months"
    }
  ],
  "dashboard_stats": {
    "has_history": true,
    "total_predictions": 30,
    "evaluated": 0,
    "pending": 30,
    "correct": 0,
    "incorrect": 0,
    "inconclusive": 0,
    "win_rate": null,
    "per_signal": {
      "BUY": {
        "total": 0,
        "correct": 0,
        "decisive": 0,
        "accuracy": null,
        "avg_return": null
      },
      "HOLD": {
        "total": 0,
        "correct": 0,
        "decisive": 0,
        "accuracy": null,
        "avg_return": null
      },
      "AVOID": {
        "total": 0,
        "correct": 0,
        "decisive": 0,
        "accuracy": null,
        "avg_return": null
      }
    },
    "streaks": {
      "TKA": 2,
      "AMAT": 2,
      "GSK": 2,
      "SAF": 2,
      "AZN": 2,
      "RIO": 2,
      "FERG": 2,
      "ENR": 2,
      "EN": 2,
      "DG": 1
    },
    "weight_overrides": {},
    "active_weights": {
      "value": 25,
      "quality": 25,
      "momentum": 25,
      "catalyst": 15,
      "liquidity": 10
    },
    "base_weights": {
      "value": 25,
      "quality": 25,
      "momentum": 25,
      "catalyst": 15,
      "liquidity": 10
    },
    "recent_evaluations": [],
    "performance_timeline": [
      {
        "date": "2026-02-07",
        "win_rate": null,
        "total_predictions": 20,
        "evaluated": 0,
        "correct": 0,
        "avg_return": null,
        "buy_accuracy": null,
        "hold_accuracy": null,
        "avoid_accuracy": null
      },
      {
        "date": "2026-02-08",
        "win_rate": null,
        "total_predictions": 30,
        "evaluated": 0,
        "correct": 0,
        "avg_return": null,
        "buy_accuracy": null,
        "hold_accuracy": null,
        "avoid_accuracy": null
      }
    ]
  }
}